leadf
logo-loader
viewMGC Pharmaceuticals Ltd

MGC Pharma team discuss positive interim results from ArtemiC in Phase II trial on COVID-19

MGC Pharmaceuticals Ltd's (ASX:MXC)(OTCMKTS:MGCLF) managing director Roby Zomer and clinical research officer Nadya Lisovoder discuss the next steps towards commercialising its anti-inflammatory treatment ArtemiC following the recent positive interim results from a Phase II clinical trial on COVID-19 infected patients. The Phase II double-blind, placebo-controlled clinical trial met all the primary objectives with all 10 patients in the treatment group showing significant improvement.

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.088 AUD

ASX:MXC
Market: ASX
Market Cap: $196.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharmaceuticals get set for LSE debut as first medicinal cannabis...

MGC Pharmaceuticals Ltd's (ASX:MXC) (FRA:H5O) (LON:MXC) Co-founder and MD Roby Zomer joins Proactive London to explain why the company has chosen to list on the London Stock Exchange (LSE) on Tuesday, February 9.  This move will mean the firm will become the first medicinal cannabis...

3 weeks, 3 days ago

2 min read